Early and accurate detection remains a cornerstone in the fight against cancer. Stepping into this crucial domain, Minomic has established itself as a leader in non-invasive blood tests tailored for cancer detection. Their prized possession, MiCheck, is more than just a test; it’s a testament to modern-day medical advancements. Harnessing the power of a specially designed monoclonal antibody, MiCheck can detect the presence of Glypican-1, a cancer-associated protein. Through such innovations, Minomic aspires to usher in an era where cancer detection is not just accurate but also non-intrusive.